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Cholangiocarcinoma (CCA) is an uncommon cancer and accounts only for 3% of all gastrointestinal malignancies. In this report,
we present a case of an intrahepatic cholangiocarcinoma masquerading as acute fatty liver of pregnancy (AFLP). A 38-year-old
female who is 36-week pregnant presented with a 1-week history of headache, nausea, vomiting, and right upper abdominal pain,
along with hepatomegaly. Laboratory investigations were remarkable for mild leukocytosis, hyperbilirubinemia, proteinuria, and
elevated transaminases and prothrombin time. Ultrasound of the liver revealed hepatomegaly, fatty infiltration, and a right hepatic
lobe mass. Based on the overall picture, AFLP was suspected, and the patient underwent delivery by Cesarean section. However,
bilirubin and liver enzyme levels gradually increased after delivery. MRI revealed a large dominant hepatic mass along with multiple
satellite lesions in both lobes. Biopsy revealed the presence of intrahepatic CCA. CCA presenting during pregnancy is extremely
rare with only 9 other cases reported in the literature. Therefore, the signs and symptoms can be easily confused with other more
common disorders that occur during pregnancy.

1. Introduction
Cholangiocarcinoma (CCA) is an uncommon malignancy
that arises from the epithelial cells of the biliary tree.
CCA accounts for approximately 3% of all gastrointestinal
malignancies [1, 2] and has a high mortality rate, given its
late diagnosis and refractoriness to therapy [3]. On average,
CCAs have a 5-year survival rate of 5–10% [4]. CCA presents
extremely rarely during pregnancy and can mimic other disorders, such as obstructive cholestasis or HELLP syndrome
[5, 6], which can lead to delayed diagnosis. We present a
case of intrahepatic CCA that mimicked acute fatty liver
of pregnancy (AFLP) and was subsequently diagnosed after
delivery.

2. Case Presentation
A 38-year-old female with morbid obesity and chronic
hypertension presented in her fourth pregnancy at 36 weeks

of gestation with a 1-week history of mild headache, nausea,
epigastric and right upper quadrant pain, and dark urine.
The pain started gradually but was constant and sharp
in nature. Upon physical examination, she was jaundiced.
The abdominal exam was remarkable for hepatomegaly and
a gravid uterus. The neurological exam was normal. The
patient denied use of any hepatotoxic medications. Her
labs were completely normal about three weeks earlier.
Initial laboratory workup showed a leucocyte count of 12.0
× 109 /L (70% neutrophils), platelet count of 450 × 109 /L,
hemoglobin of 11.5 g/dL, total bilirubin of 6.4 mg/dl (direct
fraction 5.0 mg/dL), aspartate aminotransferase (AST) of
83 U/L, alanine aminotransferase (ALT) of 87 U/L, alkaline
phosphatase (ALP) of 319 U/l, glucose of 66 mg/dL, LDH
of 679 U/L, uric acid of 4.2 mg/dL, and total serum bile
acids of 71 𝜇mol/L (ref. 0–19 𝜇mol). Prothrombin time was
17 seconds with an international normalized ratio (INR)
of 1.4. Viral hepatitis serology, autoimmune marker, and
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Figure 1: Liver ultrasound. (a) demonstrates the size of the liver measured to be about 26.2 cm. (b) demonstrates the hypoechoic mass in the
right hepatic lobe (green arrows). The mass measured 2.8 cm.

(a)

(b)

Figure 2: MRI of the liver and abdomen showing the large hepatic mass. (a) T1-weighted image. (b) T2-weighted image. The mass is involving
the majority of the left hepatic lobe, measuring approximately 11.2 × 9.2 × 5.8 cm. There are multiple additional satellite lesions within the left
hepatic lobe. There is an additional similar-appearing smaller T2 hyperintense lesion within the right hepatic lobe, measuring approximately
2.8 × 2.1 cm.

ceruloplasmin test results were unremarkable. The urine
protein-to-creatinine ratio was elevated with 24 hours of
collection for urine protein, 1300 mg/day; her 24-hour urine
protein was 180 mg/day prior to pregnancy. Ultrasonography showed marked hepatomegaly (∼27 cm), fatty infiltration of the liver, and a right hepatic hypoechoic 2.8 cm
mass (Figure 1). Moreover, the liver exhibited heterogenous
echotexture along with areas of nodular contour. Given
the patients’ clinical presentation, biochemical profile, and
imaging findings, the obstetricians suspected AFLP. The
patient underwent delivery by Cesarean section; however,
bilirubin and liver enzyme levels gradually increased after
delivery. Magnetic resonance imaging (MRI) of the liver was
obtained three days after delivery for further evaluation of the
mass and worsening liver function (Figure 2). MRI showed a
heterogeneous T2 hyperintense mass involving the majority
of the left hepatic lobe, measuring approximately 11.2 × 9.2
× 5.8 cm. There was an additional similar, smaller lesion
within the right hepatic lobe, measuring approximately 2.8
× 2.1 cm. There were additional satellite lesions within the
left hepatic lobe. There was mild, diffuse intrahepatic biliary
dilation. Serum tumor markers were obtained and showed
elevated cancer antigen 19-9 (CA19-9) of >10,000 U/ml, CEA
of 160.5 ng/mL (normal up to 5.20), and 𝛼-fetoprotein (AFP)
of 1,135 ng/mL. US guided biopsy tissue obtained from the
smaller right hepatic mass showed adenocarcinoma with an

immunohistochemical profile consistent with cholangiocarcinoma. A CT scan of the chest showed multiple bilateral
pulmonary nodules suspicious for metastasis. Total bilirubin
started to increase gradually, up to 14.0 mg/dL. The patient
underwent placement of percutaneous biliary drains with
subsequent improvement of her total bilirubin to 4.0 mg/dL.
She was then started on palliative chemotherapy with gemcitabine; however, this was complicated by recurrent episodes
of cholangitis with multidrug-resistant organisms. She also
developed progressive disease and peritoneal carcinomatosis
and was subsequently transitioned into hospice care. She died
around six months after her original presentation.

3. Discussion
CCAs can be classified based on their anatomical location, as
intrahepatic, perihilar, or distal extrahepatic [3]. The majority
of CCAs are either perihilar or distal, with intrahepatic
disease responsible for <10% of the cases [2, 7]. CCA risk
factors include, but are not limited to, primary sclerosing
cholangitis, choledocholithiasis, long-standing ulcerative colitis, infestation with Clonorchis sinensis, Caroli’s disease, and
congenital hepatic fibrosis [2, 3, 8]. In most patients, there is
no identifiable cause of CCA [2]. The clinical features of CCAs
differ according to their clinical location [2, 4]. In general,
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they are asymptomatic in the early stages and symptomatic
cases usually indicate advanced disease [2, 3]. Extrahepatic
tumors usually present with painless jaundice from biliary
obstruction [2, 4]; on the other hand, intrahepatic CCAs
are less likely to cause jaundice. Common CCA symptoms
include abdominal pain, fatigue, cachexia and/or fever, and
night sweats [2–4]. Intrahepatic CCAs can be an incidental
finding, when imaging is obtained, as part of the workup of
abnormal liver blood tests [9].
Liver diseases complicate the courses of ∼3% of all
pregnancies and some of them can have severe consequences
[9–11]. They often have very similar presentations. The most
important pregnancy-specific presentations are preeclampsia, eclampsia, hyperemesis gravidarum, AFLP, intrahepatic
cholestasis of pregnancy, and HELLP syndrome [11, 12]. Additionally, the differential diagnosis includes other disorders
that are unrelated to pregnancy, such as drugs, toxins, and
viral hepatitis. AFLP is a rare but life-threatening disease that
occurs mostly in the third trimester [11]. The usual symptoms
of AFLP are nausea, vomiting, and epigastric pain [11, 12]
and the notable laboratory features include leukocytosis,
moderate elevation in liver enzymes, hyperbilirubinemia,
coagulopathy, hyperuricemia, hypoglycemia, and proteinuria
[11–13]. Ultrasound features include increased echogenicity,
indicating fatty infiltration and sometimes ascites [11, 14].
Swansea criteria can also be used to aid the diagnosis [11].
The majority of liver masses identified during pregnancy
are more commonly benign [15], for example, hemangiomas,
adenomas, hamartomas, and focal nodular hyperplasia [15,
16]. Only a few cases of hepatocellular carcinoma were
reported in the literature [15]; given the rarity of malignant
liver lesions in pregnancy and that the presenting symptoms
of malignancy may be confused with the common symptoms
of pregnancy, the diagnosis is often delayed [5, 15]. In
addition, diagnostic and interventional modalities are limited
in pregnancy, which might be another limiting factor in early
diagnosis [16].
CCA is extremely rare during pregnancy. We searched
the PubMed database and found 9 cases in 8 reports of CCA
in pregnancy from 1975 to 2015 [5, 6, 17–22]. We analyzed
the 9 cases and the present case. The age of the women
ranged from 25 to 38. Five of the cases were diagnosed in
the second trimester and one in the third. In our case and
in the case reported by Zelissen et al., the symptoms started
in the pregnancy but the correct diagnosis was established
postpartum [18]. In one of the cases reported by Purtilo et
al., the patient died from meningitis during pregnancy and
was found to have incidental CCA during autopsy [17]. In the
other case reported by Purtilo et al., a postpartum woman had
a positive pregnancy test and a metastatic malignancy. The
diagnosis was confused with choriocarcinoma due to ectopic
secretion of human chorionic gonadotropin; the correct diagnosis was established during autopsy [17]. Common presenting symptoms and signs were nausea, vomiting, abdominal
pain, pruritus, jaundice, hepatomegaly, and/or a palpable
mass; interestingly, one of the cases presented as spinal
cord compression [21]. In the cases with reported laboratory
values, the liver enzymes (AST/ALT) were normal or slightly
elevated. Total bilirubin was elevated in five cases (range:
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3.6–15.9 mg/dL). Other abnormal lab results were malignant
hypercalcemia in one case and elevated bile acids in another
[5, 18]. The diagnosis mimicked obstetric cholestasis in one
case [5], HELLP in another [6], and acute fatty liver of
pregnancy in our case. The prognosis was generally poor: six
of the women died shortly, up to 6 months, after diagnosis.
Pregnancy may adversely affect the prognosis of hepatocellular carcinoma, as gestational immune suppression may be
an enabling factor in tumor progression [23]. This might be
also true for CCA but cannot be proven due to the paucity
of reported cases.
In conclusion, CCA presenting during pregnancy is
extremely rare; however, the signs and symptoms can be
easily confused with other more common disorders that
occur in pregnant women. In addition, pregnancy might
limit the diagnostic modalities, which can lead to delayed
diagnosis and potentially worse outcomes.
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